Individuals with the favorable NKG2A genotype (GG) had a skewed NK cell repertoire toward NKG2A+ cells, mounted higher cytokine responses against leukemic cells, and NK cells from AML patients with this genotype displayed higher accumulation of granzyme B during HDC/IL-2 immunotherapy. This evidence concerns the gene KLRC1 and acute myeloid leukemia.